SEC EDGARAUG 191 min read$SHC

Petras Michael B. Jr. sold $15.7M of SHC (indirect holdings)

Petras Michael B. Jr. (Executive Chairman) sold 850,000 indirectly-held shares of Sotera Health Co (SHC) at $18.50 ($15.73M total) on 2026-08-17.

Original reporting

SEC EDGAR · Petras Michael B. Jr.

Published Aug 19, 2026, 8:24 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 19, 2026, 8:58 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$SHC

Bearish

medium confidence

Mentioned

$SHC

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$SHCBearishLow

Why it matters

The sale reduces insider ownership, which may be interpreted as a bearish sign.

Market read

Direct impact on SHC stock; limited broader market effect.

What to watch

No accompanying earnings or guidance change; market may discount the sell.

Relevance 7/10Novelty 6/10Timing: post-market 2026-08-17

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SHCBearishMedium confidence

Context

Executive Chairman sold 850,000 shares for $15.7M, reducing his stake to 3.97M shares.

Expected impact

Potential modest decline in SHC price over the next few days.

Evidence & confidence

Significant insider sell by a top executive often signals lack of confidence, but no other catalyst is present.

Market effects

Sector

Minimal impact on healthcare services sector.

Regional

US market only.

Global

Low

Counterpoint

What could challenge this read

Insider sell could be routine diversification, not a negative signal.

Key entities

Executive Chairman
Petras Michael B. Jr.
Reported insider sale of SHC shares.

Read at source ← All news

OCT 14

High

Sotera Health Shares Fall After JPMorgan Downgrade

Sotera Health's shares declined after JPMorgan downgraded the company to 'Underweight' from 'Neutral' and set a price target of $17. The stock is currently trading at $17.76, down 2.44% on the day and 1.15% over the past year.

marketscreener.com1 min

OCT 14

$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

tradingview.com2 min

SEP 8

$SHCMed

Piper Sandler reiterates Sotera Health stock rating on growth outlook

Piper Sandler reiterated an Overweight rating and $25.00 price target on Sotera Health (SHC), suggesting 19% upside. The firm cited strong growth, management's strategy, and positive free cash flow outlook. SHC reported Q2 earnings beating estimates, with revenue up 9.2% YoY. Management raised its 2026 outlook and announced reaching long-term leverage targets.

investing.com2 min

AUG 31

$TECHMed

Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks

Bio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.

yahoo.com3 min

AUG 19

$AVTRMed

Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.